Suven Life Sciences has bagged two patents viz. US 7,388,024 and US 7,507,835 by US Patent Office equivalent to two New Chemical Entities for the cure of disorders related with Neurodegenerative ailments and these patents are applicable until 2024 and 2022 correspondingly.

Suven Life Sciences Lmtd declared that its drug breakthrough partnership in central nervous system disarray with the Eli Lilly and Company produced an optimistic result with major announcement driving to a milestone imbursement to Suven.

Suven Life Sciences presently trades at Rs.16.92, which is high by 2.82 points from its last close of Rs.14.10 on the Sensex.